CAS: 1353018-10-6

Thiosildenafil-despiperazine is a derivative of sildenafil, which is a phosphodiesterase type 5 (PDE5) inhibitor. This compound is synthesized through structural modifications of sildenafil, leading to alterations in its pharmacological profile and potential applications. The source of this derivative involves chemical synthesis techniques to modify the core structure of sildenafil, specifically targeting modifications in the piperazine ring and replacing it with a thioside group to enhance or alter desired effects. The mode of action of Thiosildenafil-despiperazine primarily revolves around its ability to inhibit PDE5. This inhibition results in the increased availability of cyclic guanosine monophosphate (cGMP), which promotes vasodilation and relaxation of smooth muscle tissues. These mechanisms are crucial in the regulation of vascular tone and influence the therapeutic efficacy of the compound. Thiosildenafil-despiperazine is explored primarily for its potential in treating conditions related to erectile dysfunction and pulmonary arterial hypertension. Its unique structural modifications may afford it distinct pharmacokinetic properties, offering potential advantages like altered absorption or distribution profiles. Ongoing research investigates its efficacy and safety, examining how these modifications impact the compound's potential therapeutic benefits over traditional PDE5 inhibitors.